BioLineRx (NASDAQ:BLRX) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of BioLineRx (NASDAQ:BLRX) in a report released on Saturday. The brokerage issued a sell rating on the biotechnology company’s stock.

BLRX has been the subject of several other reports. Jones Trading restated a “hold” rating on shares of BioLineRx in a report on Wednesday, April 2nd. HC Wainwright boosted their target price on shares of BioLineRx from $9.00 to $26.00 and gave the company a “buy” rating in a report on Monday, March 31st.

BioLineRx Stock Down 2.5%

BLRX stock opened at $3.09 on Friday. BioLineRx has a one year low of $2.30 and a one year high of $35.60. The stock has a market capitalization of $10.29 million, a PE ratio of -0.35 and a beta of 1.15. The company has a debt-to-equity ratio of 2.11, a quick ratio of 1.37 and a current ratio of 1.52. The company has a fifty day moving average of $3.06 and a 200-day moving average of $6.78.

Hedge Funds Weigh In On BioLineRx

An institutional investor recently bought a new position in BioLineRx stock. Highbridge Capital Management LLC bought a new position in BioLineRx Ltd. (NASDAQ:BLRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,010,012 shares of the biotechnology company’s stock, valued at approximately $215,000. Highbridge Capital Management LLC owned about 50.50% of BioLineRx as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 1.56% of the company’s stock.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.